Please login to the form below

Not currently logged in
Email:
Password:

rocapuldencel-T

This page shows the latest rocapuldencel-T news and features for those working in and with pharma, biotech and healthcare.

Argos hit as kidney cancer immunotherapy fails phase III trial

Argos hit as kidney cancer immunotherapy fails phase III trial

Argos Therapeutics' hopes of bringing lead cancer immunotherapy rocapuldencel-T to market anytime soon have been dashed after it flunked a pivotal phase III trial. ... Rocapuldencel-T, a personalised immunotherapy that uses individual patients' tumour

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics